TY  -  
T1  - Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN) : a double-blind, randomised, placebo-controlled phase 2b trial 
SN  -  /  
UR  - http://hdl.handle.net/10138/236232 
T3  -  
A1  - Fellstroem, Bengt C.; Barratt, Jonathan; Cook, Heather; Coppo, Rosanna; Feehally, John; de Fijter, Johan W.; Floege, Juergen; Hetzel, Gerd; Jardine, Alan G.; Locatelli, Francesco; Maes, Bart D.; Mercer, Alex; Ortiz, Fernanda; Praga, Manuel; Sorensen, Soren S.; Tesar, Vladimir; Del Vecchio, Lucia; NEFIGAN Trial Invest 
A2  -  
PB  -  
Y1  - 2017 
LA  - eng 
AB  - Background IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-20 years. In this trial (NEFIGAN) we aimed to assess safety and efficacy of a novel targeted-release formulation of budesonide (TRF-budesonide), designed to deliver the drug to the distal ileum in patients with IgA nephropathy. Methods We did a randomised, double-blind, placebo-c... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - IMMUNOGLOBULIN-A NEPHROPATHY; LONG-TERM; RENAL SURVIVAL; KIDNEY-DISEASE; RISK; THERAPY; PHARMACOKINETICS; PROTEINURIA; ANTIBODIES; HEMATURIA; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -